Vile R - Search Results

1

Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Willmon C, et al. Among authors: vile r. Mol Ther. 2009 Oct;17(10):1667-76. doi: 10.1038/mt.2009.194. Epub 2009 Aug 18. Mol Ther. 2009. PMID: 19690519 Free PMC article. Review.

2

A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model.

Castleden SA, Chong H, Garcia-Ribas I, Melcher AA, Hutchinson G, Roberts B, Hart IR, Vile RG. Castleden SA, et al. Among authors: vile rg. Hum Gene Ther. 1997 Nov 20;8(17):2087-102. doi: 10.1089/hum.1997.8.17-2087. Hum Gene Ther. 1997. PMID: 9414257

3

Gene therapy for cancer--managing expectations.

Melcher AA, Garcia-Ribas I, Vile RG. Melcher AA, et al. Among authors: vile rg. BMJ. 1997 Dec 13;315(7122):1604-7. doi: 10.1136/bmj.315.7122.1604. BMJ. 1997. PMID: 9437283 Free PMC article. Review. No abstract available.

4

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression.

Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Melcher A, et al. Among authors: vile rg. Nat Med. 1998 May;4(5):581-7. doi: 10.1038/nm0598-581. Nat Med. 1998. PMID: 9585232

5

Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.

Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG. Melcher A, et al. Among authors: vile rg. Cancer Res. 1999 Jun 15;59(12):2802-5. Cancer Res. 1999. PMID: 10383135

6

Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors.

Melcher A, Murphy S, Vile R. Melcher A, et al. Among authors: vile r. Hum Gene Ther. 1999 Jun 10;10(9):1431-42. doi: 10.1089/10430349950017770. Hum Gene Ther. 1999. PMID: 10395369

7

Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake.

Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG. Todryk S, et al. Among authors: vile rg. J Immunol. 1999 Aug 1;163(3):1398-408. J Immunol. 1999. PMID: 10415040

8

Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors.

Peng KW, Vile R, Cosset FL, Russell S. Peng KW, et al. Among authors: vile r. Gene Ther. 1999 Sep;6(9):1552-7. doi: 10.1038/sj.gt.3300982. Gene Ther. 1999. PMID: 10490764

9

Cancer gene therapy: hard lessons and new courses.

Vile RG, Russell SJ, Lemoine NR. Vile RG, et al. Gene Ther. 2000 Jan;7(1):2-8. doi: 10.1038/sj.gt.3301084. Gene Ther. 2000. PMID: 10680008 Review.

10

Apoptosis or necrosis for tumor immunotherapy: what's in a name?

Melcher A, Gough M, Todryk S, Vile R. Melcher A, et al. Among authors: vile r. J Mol Med (Berl). 1999 Dec;77(12):824-33. doi: 10.1007/s001099900066. J Mol Med (Berl). 1999. PMID: 10682318 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

312 results

Search Page

Filters